Equipment Photos From The Past
Peptide Synthesis has evolved and grown!
Please view some great photography from Chemistry History Files
“For many years,
peptide‐based therapies were regarded as being
limited to the treatment of hormonal lesions and later
hormone‐dependent cancer. Other indications were
not obvious at the time. In addition, peptides – due
to their chemical structure – were expensive and
complicated pharmaceuticals to manufacture. They
also often had exceptionally short half‐lives making
chronic administration problematic and costly.
We can expect the number of peptides entering
clinical trials to grow. We can expect the overall
complexity of peptide APIs, their potency (by design)
and their specificity (including the ability to target
specific organs and cells) to increase. The use of
peptides conjugated to PEGs, carbohydrates, antibod‐
ies and other proteins will become more frequent.
Peptides will not only be used as the active ingredient
of new drugs, but as “add‐ons” to other pharmaceu‐
tical agents to direct them to their targets, to ferry
them across cellular membranes, and to modify their
We expect the range of medical indications that
peptides address to grow. We can expect peptide‐
based antimicrobial peptides to find commercial use.
Almost certainly peptides will find increased usage
to treat obesity, metabolic syndromes and Type 2 diabetes.
The use of membrane‐penetrating peptides will increase
the number of intracellular targets. Peptides will be
used to address currently “undruggable” targets.” – Rodney Lax, PhD Polypeptide
Advanced ChemTech Chemistry